Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review
MCC950 has been proposed as a specific small molecule inhibitor that can selectively block NLRP3 inflammasome activation. However, the exact mechanism of its action is still ambiguous. Accumulating investigations imply that chloride efflux–dependent ASC speck oligomerization and potassium efflux–dependent activation of caspase-1 are the two relatively independent, but indispensable events for NLRP3 inflammasome activation. Previous studies suggested that influence of MCC950 on potassium efflux and its consequent events such as interaction between NEK7 and NLRP3 are limited. However, inhibiting chloride intracellular channel–dependent chloride efflux leads to a modification of inflammatory response, which is similar to the function of MCC950. Based on these findings, we shed new insights on the understanding of MCC950 that its function might correlate with chloride efflux, chloride intracellular channels, or other targets that act upstream of chloride efflux.
KEY WORDSNLRP3 MCC950 potassium efflux NEK7 ASC chloride efflux
This work was supported by the National Natural Science Foundation of China (No. 81873130, No. 81573733, No. 81804025), Tianjin Municipal Natural Science Foundation (No. 18JCYBJC94500), Scientific and Technological Research Program of Tianjin Municipal Education Commission (No. 2017KJ164), and 2017 Annual Graduate Students Innovation Fund (School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; No. CXJJLX201701).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Sharma BR, Karki R, Kanneganti TD. 2019. Role of AIM2 inflammasome in inflammatory diseases, cancer and infection. European Journal of Immunology.Google Scholar
- 9.Perera, A.P., R. Fernando, T. Shinde, R. Gundamaraju, B. Southam, S.S. Sohal, A.A.B. Robertson, K. Schroder, D. Kunde, and R. Eri. 2018. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Scientific Reports 8: 8618.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Coates, B.M., K.L. Staricha, N. Ravindran, C.M. Koch, Y. Cheng, J.M. Davis, D.K. Shumaker, and K.M. Ridge. 2017. Inhibition of the NOD-like receptor protein 3 inflammasome is protective in juvenile influenza A virus infection. Scientific Reports 8: 782.Google Scholar
- 11.Honda, H., Y. Nagai, T. Matsunaga, N. Okamoto, Y. Watanabe, K. Tsuneyama, H. Hayashi, I. Fujii, M. Ikutani, Y. Hirai, A. Muraguchi, and K. Takatsu. 2014. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. Journal of Leukocyte Biology 96: 1087–1100.CrossRefGoogle Scholar
- 13.Coll, R.C., A.A. Robertson, J.J. Chae, S.C. Higgins, R. Munoz-Planillo, M.C. Inserra, I. Vetter, L.S. Dungan, B.G. Monks, A. Stutz, D.E. Croker, M.S. Butler, M. Haneklaus, C.E. Sutton, G. Nunez, E. Latz, D.L. Kastner, K.H. Mills, S.L. Masters, K. Schroder, M.A. Cooper, and L.A. O'Neill. 2015. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21: 248–255.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Perregaux, D.G., P. McNiff, R. Laliberte, N. Hawryluk, H. Peurano, E. Stam, J. Eggler, R. Griffiths, M.A. Dombroski, and C.A. Gabel. 2001. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 299: 187–197.PubMedGoogle Scholar
- 15.Primiano, M.J., and B.A. Lefker. 2016. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary. Inflammation. 197: 2421–2433.Google Scholar
- 16.van der Heijden, T., E. Kritikou, W. Venema, J. van Duijn, P.J. van Santbrink, B. Slutter, A.C. Foks, I. Bot, and J. Kuiper. 2017. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report. Arteriosclerosis, Thrombosis, and Vascular Biology 37: 1457–1461.CrossRefGoogle Scholar
- 30.Shi, H., Y. Wang, X. Li, X. Zhan, M. Tang, M. Fina, L. Su, D. Pratt, C.H. Bu, S. Hildebrand, S. Lyon, L. Scott, J. Quan, Q. Sun, J. Russell, S. Arnett, P. Jurek, D. Chen, V.V. Kravchenko, J.C. Mathison, E.M. Moresco, N.L. Monson, R.J. Ulevitch, and B. Beutler. 2016. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nature Immunology 17: 250–258.CrossRefGoogle Scholar
- 31.Green, J.P., S. Yu, F. Martin-Sanchez, P. Pelegrin, G. Lopez-Castejon, C.B. Lawrence, and D. Brough. 2018. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming. Proceedings of the National Academy of Sciences of the United States of America 115: E9371–E9E80.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Masumoto, J., S. Taniguchi, K. Ayukawa, H. Sarvotham, T. Kishino, N. Niikawa, E. Hidaka, T. Katsuyama, T. Higuchi, and J. Sagara. 1999. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. The Journal of Biological Chemistry. 274: 33835–33838.CrossRefGoogle Scholar
- 40.Daniels, M.J., J. Rivers-Auty, T. Schilling, N.G. Spencer, W. Watremez, V. Fasolino, S.J. Booth, C.S. White, A.G. Baldwin, S. Freeman, R. Wong, C. Latta, S. Yu, J. Jackson, N. Fischer, V. Koziel, T. Pillot, J. Bagnall, S.M. Allan, P. Paszek, J. Galea, M.K. Harte, C. Eder, C.B. Lawrence, and D. Brough. 2016. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nature Communications 7: 12504.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Laliberte, R.E., D.G. Perregaux, L.R. Hoth, P.J. Rosner, C.K. Jordan, K.M. Peese, J.F. Eggler, M.A. Dombroski, K.F. Geoghegan, and C.A. Gabel. 2003. Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. The Journal of Biological Chemistry. 278: 16567–16578.CrossRefGoogle Scholar
- 42.Domingo-Fernandez, R., R.C. Coll, J. Kearney, S. Breit, and L.A.J. O'Neill. 2017. The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1beta transcription and activate the NLRP3 inflammasome. The Journal of Biological Chemistry. 292: 12077–12087.CrossRefPubMedPubMedCentralGoogle Scholar